OpenBit ResearchOpenBit
中文

What's driving Ultragenyx Pharmaceutical (RARE)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Can FAYUVI establish Ultragenyx's gene-therapy commercial trajectory?

Why it matters now

FAYUVI approval and potential treatment adoption directly affect Ultragenyx revenue; the approval and clinical evidence may also affect valuation_multiple through the company's gene-therapy platform.

Next checkpoint

RARE earnings (expected 2026-11-03)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to RARE, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Treatment-center rollout does not translate into meaningful treatment use, or subsequent evidence materially undermines the reported clinical benefit.

Research drivers

  • Can FAYUVI establish Ultragenyx's gene-therapy commercial trajectory?

    Bullish · Active · Updated

    FAYUVI has regulatory approval and reported clinical evidence supporting a commercial gene-therapy trajectory, while adoption remains to be demonstrated.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • The FDA approval marks Ultragenyx’s second gene therapy success and includes a Priority Review Voucher.

    Relayed by: Benzinga · Event date on record:

  • FAYUVI’s approval rests on data from the pivotal Transpher A trial and long-term follow-up extending to nearly eight years.

    Relayed by: Benzinga · Event date on record:

  • In the mITT population of 17 patients, FAYUVI-treated patients showed a 23.5-point higher Bayley-III cognitive score than an external untreated natural-history cohort of 27 patients, with p<0.0001.

    Relayed by: Benzinga · Event date on record:

  • FAYUVI is a single-dose AAV9 gene therapy designed for children with mucopolysaccharidosis type IIIA.

    Relayed by: Benzinga · Event date on record:

  • The FDA fully approved Ultragenyx Pharmaceutical’s FAYUVI (rebisufligene etisparvovec-hopf), the first treatment for Sanfilippo syndrome Type A.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.